ESMA has started publishing the list of questions received through its question and answer (Q&A) process. The questions are grouped by topic or legislative act—namely, including Corporate Disclosure, Credit Rating Agencies, Fund Management, MiFID and Investor Protection, MiFID/MiFIR and Secondary Markets, Market Abuse Regulation, Benchmarks Regulation, Short Selling Regulation, Post Trading, Innovation and Products, Prospectus Regulation, and Securitization Regulation. In case updates are required, ESMA will update the Q&A weekly.
This publication comes in the context of the entry into force of the revised ESMA regulation, which includes the new provisions applicable to Q&A. The new provisions require ESMA to setup a web-based tool to facilitate the submission of questions and to publish questions received, along with answers to the admissible questions. Q&As constitute a form of guidance on the acts within the remit of ESMA. As is the case with other forms of guidance, Q&As are adopted by the ESMA Board of Supervisors. Q&As are not legally binding, yet their application will be rigorously scrutinized by ESMA and national competent authorities, given their practical significance to achieve a level playing field. In the areas where ESMA is the direct supervisor of financial market participants, Q&As act to inform its approach.
ESMA is committed to implementing this web-based tool and is working on developing the necessary IT infrastructure. The roll-out of the IT infrastructure will be done on a phased basis and during the year. Pending the full implementation of this web-based tool, stakeholders can continue submitting questions to ESMA through the Q&A webpage of the ESMA website. ESMA has started publishing, in advance, on its website the following questions:
- Questions for which a Q&A will be put on the agenda of the relevant Standing Committee of ESMA
- Rejected questions—that is, questions that were tabled for discussions in an ESMA Standing Committee and to which ESMA does not intend to provide an answer
- Questions forwarded to EC
Keywords: Europe, Banking, Securities, Q&A, Securitization Regulation, Benchmark Regulation, Credit Rating Agencies, Big Data, Fintech, ESMA
APRA has concluded its review of the comprehensive plans of authorized deposit-taking institutions for the assessment and management of loans with repayment deferrals.
ESAs (EBA, EIOPA, and ESMA) published the first joint report that assesses risks in the financial sector since the outbreak of the COVID-19 pandemic.
BoE and HM Treasury confirmed that the COVID Corporate Financing Facility (CCFF) will close for new purchases of commercial paper, with effect from March 23, 2021.
ECB published a decision allowing the euro area banks under its direct supervision to exclude certain central bank exposures from the leverage ratio.
ESAs launched a survey seeking feedback on the presentational aspects of product templates under the Sustainable Finance Disclosure Regulation (SFDR or Regulation 2019/2088).
ECB published input of the European System of Central Banks (ESCB) into the EBA feasibility report on reducing the reporting burden for banks in EU.
EC adopted a decision determining, for a limited period of time, that the regulatory framework applicable to central counterparties, or CCPs, in the UK and Northern Ireland is equivalent to the requirements laid down in the European Market Infrastructure Regulation (EMIR or Regulation 648/2012).
EBA has decided to phase out the guidelines on legislative and non-legislative moratoria of loan repayments, in accordance with the earlier specified end of September deadline.
EBA published an Opinion addressed to EC to raise awareness about the opportunity to clarify certain issues related to the definition of credit institution in the upcoming review of the Capital Requirements Directive and Regulation (CRD and CRR).
ECB finalized the guide on assessment methodology for the internal model method for calculating exposure to counterparty credit risk (CCR) and the advanced method for own funds requirements for credit valuation adjustment (A-CVA) risk.